Literature DB >> 5254045

Vincristine and prednisone for the induction of remissions in acute childhood leukaemia.

R M Hardisty, T J McElwain, C W Darby.   

Abstract

A total of 65 children with acute lymphoblastic leukaemia and seven with other types of acute leukaemia received treatment with a combination of vincristine and prednisone. In all 122 courses of treatment were given. Of 22 patients with acute lymphoblastic leukaemia who received this as their first treatment, all achieved complete remission. The complete remission rates were 82% for patients with acute lymphoblastic leukaemia in their first relapse, 63% in the second relapse, and much lower in subsequent relapses and in the patients with other types of acute leukaemia. Alopecia and gastrointestinal and neuromuscular toxicity occurred respectively in 51%, 29%, and 21% of instances, only the last of these side-effects of vincristine being dose-related. Most of the complete remissions were obtained with a total dose of vincristine which carried only a low risk of neurotoxicity.

Entities:  

Mesh:

Substances:

Year:  1969        PMID: 5254045      PMCID: PMC1983668          DOI: 10.1136/bmj.2.5658.662

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  9 in total

1.  Clinical studies with vincristine.

Authors:  P P CARBONE; V BONO; E FREI; C O BRINDLEY
Journal:  Blood       Date:  1963-05       Impact factor: 22.113

2.  VINCRISTINE IN THE TREATMENT OF ACUTE LEUKEMIA IN CHILDREN.

Authors:  A E EVANS; S FARBER; S BRUNET; P J MARIANO
Journal:  Cancer       Date:  1963-10       Impact factor: 6.860

3.  Maintenance therapy in acute leukemia of childhood. Comparison of cyclic vs. sequential methods.

Authors:  W Krivit; C Brubaker; L G Thatcher; M Pierce; E Perrin; J R Hartmann
Journal:  Cancer       Date:  1968-03       Impact factor: 6.860

4.  Vincristine in acute leukemia of childhood.

Authors:  M E Haggard; D J Fernbach; T M Holcomb; W W Sutow; T J Vietti; J Windmiller
Journal:  Cancer       Date:  1968-08       Impact factor: 6.860

5.  The effectiveness of combinations of antileukemic agents in inducing and maintaining remission in children with acute leukemia.

Authors:  E Frei; M Karon; R H Levin; E J Freireich; R J Taylor; J Hananian; O Selawry; J F Holland; B Hoogstraten; I J Wolman; E Abir; A Sawitsky; S Lee; S D Mills; E O Burgert; C L Spurr; R B Patterson; F G Ebaugh; G W James; J H Moon
Journal:  Blood       Date:  1965-11       Impact factor: 22.113

6.  The role of vincristine in the treatment of childhood acute leukemia.

Authors:  M Karon; E J Freireich; E Frei; R Taylor; I J Wolman; I Djerassi; S L Lee; A Sawitsky; J Hananian; O Selawry; D James; P George; R B Patterson; O Burgert; F I Haurani; R A Oberfield; C T Macy; B Hoogstraten; J Blom
Journal:  Clin Pharmacol Ther       Date:  1966 May-Jun       Impact factor: 6.875

7.  Effectiveness of vincristine (NSC-67574) against refractory leukemia in children.

Authors:  M Karon
Journal:  Cancer Chemother Rep       Date:  1968-06

8.  Combination chemotherapy of acute lymphocytic leukemia of childhood.

Authors:  E S Henderson
Journal:  Cancer Res       Date:  1967-12       Impact factor: 12.701

9.  Induction of remission in acute leukemia of childhood by combination of prednisone and either 6-mercaptopurine or methotrexate.

Authors:  W Krivit; C Brubaker; J Hartmann; M L Murphy; M Pierce; G Thatcher
Journal:  J Pediatr       Date:  1966-06       Impact factor: 4.406

  9 in total
  4 in total

1.  Adriamycin in the treatment of acute leukaemia.

Authors:  J M Whitehouse; D Crowther; C J Bateman; M E Beard; J S Malpas
Journal:  Br Med J       Date:  1972-02-19

2.  Acute encephalopathy associated with continuous vincristine sulfate combination therapy: case report.

Authors:  W Scheithauer; H Ludwig; E Maida
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

3.  High incidence of vincristine-induced neuropathy in lymphomas.

Authors:  S M Watkins; J P Griffin
Journal:  Br Med J       Date:  1978-03-11

4.  Treatment of acute lymphoblastic leukemia with an rGel/BLyS fusion toxin.

Authors:  R Parameswaran; M Yu; M-A Lyu; M Lim; M G Rosenblum; J Groffen; N Heisterkamp
Journal:  Leukemia       Date:  2012-02-29       Impact factor: 11.528

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.